AT501170T - Method for the production of humanized antibodies by randomized mutagenesis - Google Patents

Method for the production of humanized antibodies by randomized mutagenesis

Info

Publication number
AT501170T
AT501170T AT05077948T AT05077948T AT501170T AT 501170 T AT501170 T AT 501170T AT 05077948 T AT05077948 T AT 05077948T AT 05077948 T AT05077948 T AT 05077948T AT 501170 T AT501170 T AT 501170T
Authority
AT
Austria
Prior art keywords
production
method
humanized antibodies
randomized mutagenesis
randomized
Prior art date
Application number
AT05077948T
Other languages
German (de)
Inventor
James A Wells
Manuel Baca
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US83350497A priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AT501170T publication Critical patent/AT501170T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
AT05077948T 1997-04-07 1998-04-03 Method for the production of humanized antibodies by randomized mutagenesis AT501170T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US83350497A true 1997-04-07 1997-04-07

Publications (1)

Publication Number Publication Date
AT501170T true AT501170T (en) 2011-03-15

Family

ID=25264594

Family Applications (4)

Application Number Title Priority Date Filing Date
AT05077948T AT501170T (en) 1997-04-07 1998-04-03 Method for the production of humanized antibodies by randomized mutagenesis
AT06024703T AT476664T (en) 1997-04-07 1998-04-03 Anti-vegf antibodies
AT98918013T AT314395T (en) 1997-04-07 1998-04-03 Humanized antibodies and method for their manufacture
AT10007444T AT541586T (en) 1997-04-07 1998-04-03 Container with anti-vegf antibodies

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT06024703T AT476664T (en) 1997-04-07 1998-04-03 Anti-vegf antibodies
AT98918013T AT314395T (en) 1997-04-07 1998-04-03 Humanized antibodies and method for their manufacture
AT10007444T AT541586T (en) 1997-04-07 1998-04-03 Container with anti-vegf antibodies

Country Status (23)

Country Link
EP (6) EP1695985B1 (en)
JP (1) JP4191258B2 (en)
KR (2) KR100856995B1 (en)
CN (6) CN101665536B (en)
AT (4) AT501170T (en)
AU (1) AU740738B2 (en)
BR (1) BR9809388B1 (en)
CA (1) CA2286397C (en)
CY (3) CY1111345T1 (en)
DE (3) DE69842174D1 (en)
DK (4) DK1695985T3 (en)
ES (4) ES2361267T3 (en)
GE (1) GEPI20105118B (en)
HK (7) HK1025338A1 (en)
IL (3) IL132239D0 (en)
LT (1) LTPA2007004I1 (en)
NO (3) NO325823B1 (en)
NZ (1) NZ500077A (en)
PT (5) PT1787999E (en)
SI (5) SI1787999T1 (en)
TR (1) TR199902818T2 (en)
WO (1) WO1998045332A2 (en)
ZA (2) ZA9802908B (en)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2361267T3 (en) * 1997-04-07 2011-06-15 Genentech Inc. Procedure for the production of humanized antibodies through random mutagenesis.
DK0973804T3 (en) * 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2792747A1 (en) 2000-06-23 2014-10-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2016951T3 (en) 1998-03-17 2012-09-24 Genentech Inc VEGF and BMP1 homologous polypeptides
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US20030158382A1 (en) 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2006506943A (en) * 2002-02-11 2006-03-02 ジェネンテック・インコーポレーテッドGenentech,Inc. Antibody variants with high antigen binding rate
CA2487321A1 (en) 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CN101274098A (en) 2003-05-30 2008-10-01 健泰科生物技术公司 Treatment with anti-VEGF antibodies
AU2004280333A1 (en) * 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
PL1697507T3 (en) 2003-12-02 2013-03-29 Pasteur Institut Use of proteins and peptides coded by the genome of a novel strain of sars-associated coronavirus
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2172482A1 (en) 2004-07-20 2010-04-07 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
PT1802334E (en) 2004-10-21 2012-11-28 Genentech Inc Method for treating intraocular neovascular diseases
CN102304184A (en) 2005-11-08 2012-01-04 健泰科生物技术公司 Neuropilin antagonists
JP5164856B2 (en) 2006-01-05 2013-03-21 ジェネンテック, インコーポレイテッド Anti-EPHB4 antibody and method of use thereof
BRPI0706935A2 (en) 2006-01-20 2011-04-19 Genentech Inc anti-ephrine b2 antibodies isolated, vector, host cell, anti-ephrine b2 antibody preparation method, anti-ephrine b2 immunoconjugate preparation method, ephrine b2 detection method, dysfunction diagnostic method, composition, inhibition method of angiogenesis and use of anti-ephrine b2 antibody
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc Egfl7 antibodies and methods of use
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
PE20080262A1 (en) * 2006-05-25 2008-04-30 Glaxo Group Ltd Humanized antibody against interleukin-18
US7803377B2 (en) 2006-06-06 2010-09-28 Genentech, Inc. Anti-DLL4 antibodies and methods using same
CN1903880B (en) * 2006-08-02 2010-05-12 中国人民解放军军事医学科学院基础医学研究所 Antitumour vascular endothelial growth factor VEGF-E antigen, its coding gene and application
CA2660681A1 (en) 2006-08-21 2008-02-28 F.Hoffmann-La Roche Ag Tumor therapy with an anti-vegf antibody
CN101148474B (en) * 2006-09-21 2014-06-11 上海杰隆生物工程股份有限公司 Human resource vessel endothelium growth factor monoclonal antibody and preparation method thereof
NZ578472A (en) 2006-12-19 2012-06-29 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
EP2158215B1 (en) 2007-05-17 2015-04-22 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
EP2152307B1 (en) 2007-05-17 2014-04-16 Genentech, Inc. Inhibition of tumor metastasis by anti neuropilin 2 antibodies
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc Anti-notch1 nrr, preparation method and pharmaceutical composition
DK2215117T4 (en) 2007-10-30 2018-04-09 Genentech Inc Antisto purification by cation change chromatography
JP5611047B2 (en) 2007-11-09 2014-10-22 ジェネンテック, インコーポレイテッド Activin receptor-like kinase-1 antagonist composition and method of use thereof
TWI468417B (en) 2007-11-30 2015-01-11 Genentech Inc Anti-vegf antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102245208B (en) 2008-10-14 2016-03-16 霍夫曼-拉罗奇有限公司 immunoglobulin variants and uses thereof
CA2744158A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Anti-angiogenesis therapy for the treatment of breast cancer
KR20140020368A (en) 2008-12-23 2014-02-18 제넨테크, 인크. Methods and compositions for diagnostic use in cancer patients
AU2010230563A1 (en) 2009-04-02 2011-09-22 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain Fab fragments
AU2010230855A1 (en) * 2009-04-03 2012-01-12 Vegenics Limited Anti-VEGF-D antibodies
ES2537100T3 (en) 2009-04-07 2015-06-02 Roche Glycart Ag Trivalent bispecific antibodies
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
PE20120902A1 (en) 2009-05-08 2012-08-08 Genentech Inc Humanized anti-egfl7
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP5785941B2 (en) * 2009-06-17 2015-09-30 アッヴィ・バイオセラピューティクス・インコーポレイテッド Anti-VEGF antibodies and uses thereof
BR112012000735A2 (en) 2009-07-13 2016-11-16 Genentech Inc "compound methods, kits and sets"
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
EP2459591B1 (en) 2009-07-31 2014-08-20 Genentech, Inc. Inhibition of tumor metastasis using anti-g-csf-antibodies
TW201431558A (en) 2009-08-15 2014-08-16 Genentech Inc Anti-angiogenesis therapy for the treatment of previously treated breast cancer
EP2475996A1 (en) 2009-09-11 2012-07-18 F.Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US20110064732A1 (en) 2009-09-17 2011-03-17 Sanne Lysbet De Haas Methods and compositions for diagnostic use in cancer patients
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
CN102051396B (en) * 2009-11-04 2014-07-16 无锡天演生物技术有限公司 Goose-array type localized random mutation method and application thereof in monoclonal antibody molecular evolution technology
EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same
TWI623323B (en) 2009-12-21 2018-05-11 建南德克公司 Antibody formulation
AR079704A1 (en) 2009-12-23 2012-02-15 Genentech Inc Anti-Bv8 antibodies and their uses
FR2955773B1 (en) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique Molecular complex for targeting antigens to antigen-presenting cells and its applications for vaccination
KR101839161B1 (en) 2010-02-23 2018-03-16 제넨테크, 인크. Anti-angiogenesis therapy for the treatment of ovarian cancer
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche Bivalent bispecific antibodies anti-VEGF / anti-Ang-2
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag Proteins modified union which inhibit the interaction of receptor growth factor vascular endothelial glycoprotein to vegf-a
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
CN102863533B (en) * 2010-06-21 2013-12-11 中国科学技术大学 Method for humanized reform for antibody
AU2011274528B2 (en) 2010-07-09 2015-04-23 Genentech, Inc. Anti-neuropilin antibodies and methods of use
KR20130126588A (en) 2010-07-19 2013-11-20 에프. 호프만-라 로슈 아게 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
RU2013104039A (en) 2010-07-19 2014-08-27 Ф. Хоффманн-Ля Рош Аг Method for identification of a patient with an increased probability of answer to anti-cancer therapy
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
KR101586128B1 (en) 2010-08-24 2016-01-15 에프. 호프만-라 로슈 아게 Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012068032A1 (en) 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2658970B1 (en) * 2010-12-31 2016-09-28 Bioatla LLC Express humanization of antibodies
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
KR101614195B1 (en) 2011-03-29 2016-04-20 로슈 글리카트 아게 Antibody fc variants
SG194051A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and vemurafenib, and methods of use
CN103781798B (en) 2011-04-20 2018-03-13 阿塞勒隆制药公司 Endoglin polypeptide and application thereof
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc Single chain antibody, polynucleotide, vector, host cell, method of production of a single chain antibody, heteromultymer and method of production
PL2825558T3 (en) 2012-03-13 2019-11-29 Hoffmann La Roche Combination therapy for the treatment of ovarian cancer
CN104271601B (en) 2012-05-31 2020-02-04 霍夫曼-拉罗奇有限公司 Methods of treating cancer using PD-1 axis binding antagonists and VEGF antagonists
MX354862B (en) 2012-06-27 2018-03-23 Hoffmann La Roche Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof.
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CA2880767A1 (en) 2012-08-07 2014-02-13 Genentech, Inc. Combination therapy for the treatment of glioblastoma
JP2016500058A (en) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス, インコーポレイテッド Methods for producing compounds and conjugates
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
JP2016505528A (en) 2012-11-16 2016-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Picte-Spengler ligation for chemical modification of proteins
FR2998579B1 (en) 2012-11-27 2015-06-19 Commissariat Energie Atomique Method for obtaining antigen-specific human antibodies by in vitro immunization
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
KR20150131208A (en) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Antigen binding constructs to cd8
CN105209069B (en) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 Antibody formulations
MX2015015426A (en) 2013-05-23 2016-06-10 Five Prime Therapeutics Inc Methods of treating cancer.
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
JP6422956B2 (en) 2013-10-11 2018-11-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Multispecific domain exchange common variable light chain antibody
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
CN105744935A (en) 2013-11-27 2016-07-06 雷德伍德生物科技股份有限公司 Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
PL3081576T3 (en) * 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
SG11201605044RA (en) 2013-12-20 2016-07-28 Hoffmann La Roche HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
US9683048B2 (en) 2014-01-24 2017-06-20 Novartis Ag Antibody molecules to PD-1 and uses thereof
DK3116909T3 (en) 2014-03-14 2020-01-20 Novartis Ag Antibody molecules for lag-3 and applications thereof
KR20160137599A (en) 2014-03-24 2016-11-30 제넨테크, 인크. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US9975957B2 (en) 2014-03-31 2018-05-22 Genentech, Inc. Anti-OX40 antibodies and methods of use
EP3492495A1 (en) 2014-05-12 2019-06-05 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
KR20170007806A (en) 2014-06-06 2017-01-20 레드우드 바이오사이언스 인코포레이티드 Anti-her2 antibody-maytansine conjugates and methods of use thereof
EP3169801A1 (en) 2014-07-14 2017-05-24 F.Hoffmann-La Roche Ag Diagnostic methods and compositions for treatment of glioblastoma
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
JP2017524713A (en) 2014-08-12 2017-08-31 マサチューセッツ インスティテュート オブ テクノロジー Synergistic tumor treatment with IL-2 and integrin binding FC fusion protein
KR20170060042A (en) 2014-09-13 2017-05-31 노파르티스 아게 Combination therapies of alk inhibitors
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
BR112017007093A2 (en) 2014-10-08 2018-03-06 Novartis Ag compositions and methods of use for enhancing immune response and cancer therapy
JP2017536099A (en) 2014-10-14 2017-12-07 ノバルティス アーゲー Antibody molecule against PD-L1 and use thereof
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
PE20170910A1 (en) 2014-11-10 2017-07-12 Genentech Inc anti-interleukin-33 antibodies and their uses
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
AU2015369624A1 (en) 2014-12-23 2017-06-08 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US20190209697A1 (en) 2015-11-05 2019-07-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
MX2018006092A (en) 2015-11-18 2019-01-31 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist.
RU2018121813A3 (en) 2015-11-18 2020-03-05
MX2018007423A (en) 2015-12-17 2018-11-09 Novartis Ag Antibody molecules to pd-1 and uses thereof.
CA3011638A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
CN105481981B (en) * 2016-01-27 2019-03-19 中国人民解放军第二军医大学 Target VEGF bispecific antibody and application thereof
CN109154613A (en) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
JP2019524706A (en) 2016-07-08 2019-09-05 ジェネンテック, インコーポレイテッド Use of human epididymis protein 4 (HE4) to assess responsiveness of MUC16 positive cancer treatment
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
TW201811369A (en) 2016-08-12 2018-04-01 美商建南德克公司 Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
CA3049656A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
AU2018228873A1 (en) 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
AU2018290237A1 (en) 2017-06-22 2020-01-16 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
WO2019129679A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
US20200024360A1 (en) 2018-05-24 2020-01-23 Janssen Biotech, Inc. Psma binding agents and uses thereof
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag Entpd2 antibodies, combination therapies and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (en) 1979-07-11 1985-06-05 Ajinomoto Kk
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2001774C (en) * 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AT414768T (en) * 1991-04-10 2008-12-15 Scripps Research Inst Libraries of heterodimeric receptors by phagemides
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (en) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッドGenentech,Inc. Immunoglobulin variants
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (en) 1991-11-25 2002-05-29 Enzon Inc Multivalent anti-binding proteins
DE69333082T2 (en) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City Obtaining homozygotem by targeted genetic events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP1975181B1 (en) * 1992-10-28 2011-02-16 Genentech, Inc. Use of vascular endothelial cell growth factor antagonists
PL174494B1 (en) 1992-11-13 1998-08-31 Idec Pharmaceuticals Corp. Therapeutic application of chimeric and radiotracer labelled antibodies, directed against the differentation antigen limited to human lymphocytes b, for treating lymphoma from lymphocytes b
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
JPH09510093A (en) * 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド Vascular endothelial growth factor 2
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ES2361267T3 (en) * 1997-04-07 2011-06-15 Genentech Inc. Procedure for the production of humanized antibodies through random mutagenesis.

Also Published As

Publication number Publication date
SI2301580T1 (en) 2012-05-31
CN101210050B (en) 2010-12-08
EP2338915A3 (en) 2011-10-12
BR9809388A (en) 2000-06-13
HK1204329A1 (en) 2015-11-13
DK2301580T3 (en) 2012-05-14
EP0971959A1 (en) 2000-01-19
CN101838328A (en) 2010-09-22
KR100794454B1 (en) 2008-01-16
IL175906A (en) 2010-05-31
NO994870D0 (en) 1999-10-06
JP2001502922A (en) 2001-03-06
NO2019045I1 (en) 2019-12-11
PT1695985E (en) 2011-06-06
CY1111345T1 (en) 2015-08-05
EP2301580A1 (en) 2011-03-30
CA2286397C (en) 2011-02-15
DE69841815D1 (en) 2010-09-16
EP1695985A2 (en) 2006-08-30
HK1095334A1 (en) 2011-07-08
PT1787999E (en) 2010-11-11
NZ500077A (en) 2001-10-26
EP2301580B1 (en) 2012-01-18
ES2349559T3 (en) 2011-01-05
DK1787999T3 (en) 2010-11-15
SI1695985T1 (en) 2011-06-30
HK1025338A1 (en) 2006-05-12
ES2380575T3 (en) 2012-05-16
ZA9802908B (en) 1999-01-21
EP0971959B1 (en) 2005-12-28
IL132240A (en) 2006-09-05
BR9809388B1 (en) 2013-06-04
LTPA2007004I1 (en) 2019-12-27
CN101665536A (en) 2010-03-10
WO1998045332A2 (en) 1998-10-15
EP1695985A3 (en) 2006-11-22
HK1114621A1 (en) 2013-09-13
PT2301580E (en) 2012-05-02
EP2301580A9 (en) 2011-09-14
CA2286397A1 (en) 1998-10-15
TR199902818T2 (en) 2000-05-22
DE69832970T2 (en) 2006-08-10
PT973804E (en) 2007-03-30
DK0971959T3 (en) 2006-05-15
AT541586T (en) 2012-02-15
NO2017039I1 (en) 2017-08-01
AT314395T (en) 2006-01-15
IL132239D0 (en) 2001-03-19
EP2336190A2 (en) 2011-06-22
HK1139425A1 (en) 2014-03-07
EP2338915A2 (en) 2011-06-29
CN1259961A (en) 2000-07-12
KR20010006116A (en) 2001-01-26
HK1149501A1 (en) 2012-06-29
CN101210051B (en) 2012-12-26
NO994870L (en) 1999-12-06
SI1787999T1 (en) 2010-12-31
CY1111520T1 (en) 2015-08-05
ES2361267T3 (en) 2011-06-15
CN104231078A (en) 2014-12-24
EP3260468A1 (en) 2017-12-27
HK1114622A1 (en) 2011-04-01
CN101210050A (en) 2008-07-02
EP2336190A3 (en) 2011-10-05
ES2256935T3 (en) 2006-07-16
KR20010006115A (en) 2001-01-26
SI0973804T1 (en) 2007-06-30
WO1998045332A3 (en) 1998-12-03
ZA9802907B (en) 1998-10-09
NO325823B1 (en) 2008-07-21
JP4191258B2 (en) 2008-12-03
CN101210051A (en) 2008-07-02
IL175906D0 (en) 2006-10-05
CN101665536B (en) 2013-07-03
CY1112757T1 (en) 2016-02-10
NO2017039I2 (en) 2018-08-28
PT971959E (en) 2006-05-31
GEPI20105118B (en) 2010-11-25
AT476664T (en) 2010-08-15
AU740738B2 (en) 2001-11-15
CN1191276C (en) 2005-03-02
DE69842174D1 (en) 2011-04-21
DE69832970D1 (en) 2006-02-02
EP1695985B1 (en) 2011-03-09
AU7102398A (en) 1998-10-30
SI0971959T1 (en) 2006-06-30
DK1695985T3 (en) 2011-06-14
KR100856995B1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
DE69704964D1 (en) Process for the production of acryloxypropylsilanes
DE69610433D1 (en) Method for producing halogened alkans
DE69500808D1 (en) Method for the production of profiled throughouts
DE69623460D1 (en) Method for producing 3-haloalkyl-1h-pyrazole
DE69719201D1 (en) Method for producing ecteinascidine compounds
DE69603139T2 (en) Method for producing 6-methylheptan-2-on
DE69627642D1 (en) Method for producing paving
DK0959837T3 (en) Process for making reclosable absorbent garments as well as absorbent garments made by this method
EP1167537A4 (en) Process for producing monoclonal antibody
DE59506424D1 (en) Method for producing biscyanoacrylates
AT311411T (en) Continuous method for the production of organoalkoxysiloxanes
DE1042310T1 (en) Method for producing citaloprame
PT869774E (en) Method for the production of delayed libertacao particles
PT900240E (en) Process for the production of polyalcenoamines
DE69833080D1 (en) Process for the production of toner
PT971959E (en) Humanized antibodies and methods for forming humanized antibodies
AT186727T (en) Substituted 3-arylidinene-7-azaoxindol compounds and method for the production thereof
DE69730350D1 (en) Method for the production of glass
DE69803982D1 (en) Method for producing 2-alkoxyestradiols
DE69229477T2 (en) Methods for the production of humanized antibodies
RU96103683A (en) Benzotiophene compounds, method of their production, intermediate compounds, composition
AT234192T (en) Method for producing components by application technology
ZA9109299B (en) Method for the production of antibodies
HK1028419A1 (en) Method for the production of glycerol by recombinant organisms
RU97110212A (en) Method for producing isocianates

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1695985

Country of ref document: EP